An Open-label, Multi-center, Phase 2 Study of AMG 162 (denosumab) in Subjects with Giant Cell Tumor of Bone
Phase 2
- Conditions
- Giant Cell Tumor of Bone
- Registration Number
- JPRN-jRCT2080221624
- Lead Sponsor
- DAIICHISANKYO Co.,Ltd.
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Sex
- All
- Target Recruitment
- 10
Inclusion Criteria
Subjects with surgically unsalvageable Giant Cell Tumor of Bone or with surgically salvageable Giant Cell Tumor of Bone whose planned surgical procedure resulting in severe morbidity
Exclusion Criteria
Currently receiving other specific treatment for Giant Cell Tumor of Bone
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method